Mesothelioma Treatment Including Photodynamic Therapy After a Lung-Sparing Operation Improves Survival

While surgery is one of the most common treatments for pleural mesothelioma, the cancer may not always be completely surgically removed. As a result, some surgical treatment plans for mesothelioma are followed by chemotherapy or radiation therapy. Photodynamic therapy, which uses light energy to destroy cancerous cells, may also be considered as a post-surgical option to promote the death of any remaining mesothelioma cells. In a 2011 study published in the Annals of Thoracic Surgery, researchers at Pennsylvania University's Penn Medicine found that the combination of a radical pleurectomy (RP) and intraoperative photodynamic therapy (PDT) yielded superior overall survival than the combination of a modified extrapleural pneumonectomy (MEPP) and PDT. Although the patients' sexes, ages, diagnoses and treatment histories were all similar, the patients who obtained the radical pleurectomy and PDT responded more favorably to treatment. The median survival rate for the group of patients who received the MEPP was 8.4 months. At a follow-up 2.1 years after the end of treatment, a median survival rate for the patients who received a radical pleurectomy had not yet been reached. The results yielded by the radical pleurectomy and adjuvant (therapy following surgery) PDT were superior to other studies of surgical treatment plans with patients of similar demographics. Between 2004 and 2008, during which the participants obtained their mesothelioma treatment, the preferential surgical appr...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Tags: Treatment & Doctors Source Type: news

Related Links:

ConclusionsPlatinum ‐based chemotherapy followed by lung‐sparing surgery (P/D) and IMRT is a feasible and safe treatment modality that yields acceptable locoregional control in patients with locally advanced MPM; however, these results should be corroborated in larger studies.
Source: Thoracic Cancer - Category: Cancer & Oncology Authors: Tags: ORIGINAL ARTICLE Source Type: research
Abstract Malignant pleural mesothelioma (MPM) is a remarkably aggressive thoracic malignancy with a limited survival of only 5-12 months. However, MPM still remains unresponsive to conventional standards of treatment, including pleurectomy and decortication, extrapleural pneumonectomy for resectable disease with or without chemotherapy, and/or radiation therapy. The mechanism of carcinogenesis has not been fully elucidated, although approximately 80% of cases can still be linked to asbestos exposure. The tumor immune microenvironment (TME) has been proven to play an important role in MPM pathogenesis and treatment...
Source: Current Drug Targets - Category: Drugs & Pharmacology Authors: Tags: Curr Drug Targets Source Type: research
An upcoming phase III clinical trial involving the National Cancer Institute should clarify the still-debatable benefits of using radiotherapy in combination with aggressive surgery for patients with pleural mesothelioma. The trial will be the first multicenter, randomized study measuring both safety and potential survival benefits of intensity-modulated radiation therapy (IMRT) and pencil-beam scanning with pleurectomy and decortication surgery and chemotherapy. The trial is sponsored by NRG Oncology and will involve several mesothelioma specialty centers across the country. The goal is to enroll a combined 150 patients. ...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
Three of the country’s leading cancer centers have opened a collaborative clinical trial that potentially could change surgical treatment of mesothelioma. Researchers will measure the safety and efficacy of using two different immunotherapy drug regimens — Opdivo (nivolumab) and Yervoy (ipilimumab) — beginning 42 days before surgery. The hope is that at least one will make surgical resection more effective. Sidney Kimmel Cancer Center at Johns Hopkins University, MD Anderson Cancer Center at the University of Texas and Greenebaum Cancer Center at the University of Maryland are working together to enroll a...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
Memorial Sloan Kettering Cancer Center in New York City has opened its latest clinical trial for patients with pleural mesothelioma, studying the effectiveness of an immunotherapy and chemotherapy combination prior to aggressive surgery. The novel feasibility study will determine if the use of Opdivo (nivolumab) with Alimta (pemetrexed) and either cisplatin or carboplatin — without delaying scheduled surgery — can significantly extend patient survival time. The hope is to duplicate earlier effectiveness of that same combination with other cancers. “It has been tried with promising results,” Memorial...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
A promising and expensive type of immunotherapy, called CAR T-cell therapy, is now covered by Medicare. This news may affect mesothelioma patients in the future. Chimeric antigen receptor T-cell, or CAR T-cell, therapy involves the laboratory reprogramming of a patient’s T cells, which are a type of white blood cell responsible for protecting the body against infection and disease. The T cells are genetically modified to better recognize and attack cancer. The U.S. Food and Drug Administration has approved the immunotherapy procedure for non-Hodgkin lymphoma and B-cell precursor acute lymphoblastic leukemia. It is...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
Semin Respir Crit Care Med 2019; 40: 347-360 DOI: 10.1055/s-0039-1693406Malignant pleural mesothelioma is a rare cancer associated with asbestos exposure and portends a dismal prognosis. Its worldwide incidence has been increasing, and treatment options are currently suboptimal and noncurative. However, since the turn of the century, several encouraging steps have been made toward improving outcomes for mesothelioma patients. An increased understanding of disease pathophysiology has led to more accurate diagnosis and staging, and the establishment of the standard of care first-line pemetrexed/platin doublet chemotherapy re...
Source: Seminars in Respiratory and Critical Care Medicine - Category: Respiratory Medicine Authors: Tags: Review Article Source Type: research
The Princess Margaret Cancer Center in Toronto has moved from SMART to SMARTER with the recent launch of its latest clinical trial for pleural mesothelioma patients. SMARTER is the acronym for Surgery for Mesothelioma After Radiation Therapy using Extensive pleural Resection, which also describes the latest clinical trial. The phase I clinical trial is an unconventional approach to treatment of mesothelioma: Find the maximum tolerated dosage of hypofractionated radiation to stimulate the immune system before aggressive surgery. It comes on the heels of the SMART protocol, which stands for Surgery for Mesothelioma After Rad...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
Prophylactic radiotherapy — once offered routinely after invasive procedures for pleural mesothelioma — is an unnecessary treatment for patients, according to the most recent study from the United Kingdom. Results from a large, multicenter clinical trial have shown the treatment — used regularly for almost two decades — does little to prevent chest-wall metastasis that can occur with mesothelioma cancer. “This should be helpful for patients to know if their oncologist is offering something they don’t really need,” clinical oncologist Dr. Neil Bayman, associate medical director at t...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
Too many patients with pleural mesothelioma are going without treatment recommended by National Comprehensive Cancer Network guidelines, according to a recent study at Cedars-Sinai Medical Center in Los Angeles. Valuable survival time is being lost. The Annals of Thoracic Surgery published the study that looked at disparities in compliance with national treatment guidelines and their impact on overall survival. The National Comprehensive Cancer Network, along with the American Society of Clinical Oncology, recommends multimodal therapy — surgery, chemotherapy and possibly radiation therapy — for mesothelioma pa...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
More News: Asbestosis | Cancer | Cancer & Oncology | Cardiovascular & Thoracic Surgery | Chemotherapy | Environmental Health | Mesothelioma | Radiation Therapy | Study